Dan Nandan is the CEO of Staffingly, Inc. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.
2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.
Featured in Computerworld →
State of Illinois. Registered Professional Nurse
Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.
What Is Cigna Dupixent prior authorization?
Most Cigna commercial plans cover Dupixent with prior authorization. Cigna places Dupixent on the specialty tier, typically Tier 4 or Tier 5, on commercial formularies. This means higher patient cost-sharing compared to preferred brand tiers, which makes copay assistance programs particularly important for patient affordability.
Does Cigna Cover Dupixent? Formulary and Tier Placement
Most Cigna commercial plans cover Dupixent with prior authorization. Cigna places Dupixent on the specialty tier, typically Tier 4 or Tier 5, on commercial formularies. This means higher patient cost-sharing compared to preferred brand tiers, which makes copay assistance programs particularly important for patient affordability.
Cigna Medicare Advantage plans also cover Dupixent under Part D, but the criteria may differ from commercial plan requirements. Medicare Advantage formularies can have stricter step therapy, different quantity limits, or additional documentation requirements compared to commercial plans. Always check the specific formulary for the patient’s plan type.
Coverage Policy IP0453, effective January 15, 2026, is the master policy governing dupilumab coverage across Cigna plans. This is the document your PA team should reference when preparing submissions. Do not rely on what Cigna member services says by phone, because phone representatives may not have the most current policy details. The published policy is the authoritative source.
Dupixent’s list price sits at approximately $3,993 per carton of 2 injections (Regeneron WAC, January 2025). Quantity limits under CNF 149 restrict dispensing to 2 syringes per 28-day supply. Loading dose exceptions are available when clinically appropriate and documented. After PA approval, Cigna routes the prescription to Accredo, the Evernorth specialty pharmacy. Accredo processing adds 3 to 7 business days on top of the PA approval timeline. Across all major payers, 98% of commercial patients aged 18 and older have formulary coverage for Dupixent (dupixenthcp.com), though coverage does not mean automatic approval.
Cigna's Step Therapy Requirements for Dupixent by Indication
IP0453 policy criteria may differ from what Cigna member services says by phone. Always reference the published policy.
How to Submit a Dupixent PA to Cigna (Step-by-Step)
Step 1: Verify the Patient’s Cigna Plan. Before gathering documentation, confirm the plan type: commercial, marketplace, or Medicare Advantage. Each has a different formulary with different tier placement and potentially different PA criteria. Check the specific formulary for Dupixent coverage, tier level, and quantity limits. Verify whether PAs route through Cigna directly or through EviCore, because some Cigna plans delegate specialty drug PAs to EviCore, which has its own submission portal and criteria. Submitting to the wrong entity delays the process by days.
Step 2: Gather Documentation to Match IP0453. Map every piece of documentation to the specific indication criteria listed in IP0453. Include the diagnosis with ICD-10 code, prior therapies (drug name, dose, duration, clinical outcome, and reason for discontinuation), current lab values (eosinophil count for asthma, biopsy results for EoE), and clinical photos for dermatologic indications showing body surface area involvement and severity. For each prior therapy, document the specific dates the medication was tried, the duration of the trial, and the clinical response or lack thereof. Vague documentation like “patient failed topical steroids” gets denied. Specific documentation like “patient used clobetasol 0.05% cream twice daily for 8 weeks from January 15 to March 15, 2026, with no improvement in BSA involvement, which remained at 18%” gets approved.
Step 3: Submit Electronically. Use CoverMyMeds or the Cigna provider portal for electronic submission. Fax submissions have significantly higher “incomplete” denial rates because the form format limits the clinical detail you can provide. Standard electronic processing takes 3-5 business days. Expedited processing for urgent clinical need takes 24-48 hours. Confirm receipt within 24 hours of submission by checking the CoverMyMeds dashboard or calling the Cigna PA line.
Step 4: Handle Accredo Specialty Pharmacy. After PA approval, Cigna routes the prescription to Accredo, the Evernorth specialty pharmacy. Accredo processing adds 3-7 business days on top of the PA approval timeline, which means patient wait times from PA submission to medication in hand can reach 10-14 business days total. Confirm that Accredo received both the PA approval and the prescription. Provide the DUPIXENT MyWay copay assistance card during Accredo intake to reduce patient out-of-pocket cost. Without the copay card, specialty tier cost-sharing can be hundreds of dollars per fill.
Step 5: Set Up Reauthorization. Cigna requires reauthorization every 12 months. Document continued clinical benefit with current clinical measurements (EASI scores, eosinophil counts, lung function tests, depending on indication). Submit the reauthorization request 30 days before the current authorization expires to avoid gaps in therapy that could force the patient to restart the dosing schedule.
Save 40-70% with dedicated PA specialists
Book a 15-minute call. We will map your current prior authorization workflow, denial rates, and staff hours against what a dedicated team typically delivers in the first 30 days.
What to Do When Cigna Denies Dupixent (Appeal Playbook)
Common Cigna denial reasons: (1) Insufficient documentation of prior treatment failure, (2) step therapy not completed, (3) incomplete submission, (4) patient does not meet coverage criteria, (5) concurrent biologic or JAK inhibitor use.
Internal Appeal: 180 calendar days from denial. Cigna responds within 30 days (pre-service) or 60 days (post-service). Expedited: 72 hours for urgent cases. Reference IP0453 by name. Include letter of medical necessity.
Peer-to-Peer: Call Cigna’s provider line. Approximately 80% of Cigna MA PA denials are overturned on appeal. The prescribing physician should conduct the call with lab values, timeline, and guideline citations ready.
External Review (IRO): If internal appeal fails, request external review by an Independent Review Organization. Binding on Cigna.
Letter of Medical Necessity Template for Cigna: Open with patient demographics and ICD-10 code. List each prior therapy with drug name, dose, dates, and clinical outcome. Reference IP0453 by name and cite the specific criterion met (e.g., “IP0453 criterion 2.a: atopic dermatitis with BSA greater than 10% and failure of topical corticosteroids for 6 weeks”). Close with the clinical rationale for Dupixent. Keep to one page.
Cigna Dupixent Coverage Rules by State: Florida, Texas, Ohio
Florida: Cigna commercial plans follow IP0453 criteria. No state step therapy ban. 180 days for internal appeals, 4 months for external review. Florida Medicaid (separate from Cigna): MCOs like Sunshine Health and Molina have their own criteria.
Texas: HB 1763 provides step therapy override protections when step therapy is contraindicated, tried and failed, or expected to be ineffective. Texas DOI external review available after internal appeals exhausted. Texas Medicaid: separate MCO formularies.
Ohio: SB 265 provides step therapy override protections based on prior treatment history, contraindications, or clinical documentation. Ohio DOI external review available. Ohio Medicaid: MCOs include CareSource, Molina, Buckeye, and UHC Community Plan.
ICD-10 and CPT Codes for Cigna Dupixent PA
Accurate code selection is critical for Cigna Dupixent PAs because Cigna’s system cross-references ICD-10 codes against the indication criteria in IP0453. A code mismatch, such as using a general asthma code when the policy requires a severity-specific code, can trigger an automatic denial without clinical review.
ICD-10 codes by indication: – Atopic Dermatitis: L20.9 (unspecified), L20.89 (other atopic dermatitis). Use L20.89 when clinical documentation supports a more specific classification. – Asthma: J45.30 through J45.50 (moderate to severe persistent asthma). Eosinophilic documentation must accompany the code. – Eosinophilic Esophagitis: K20.0. Must be supported by endoscopy with biopsy showing 15+ eos/HPF. – CRSwNP (Nasal Polyps): J33.0 (polyp of nasal cavity) or J33.9 (nasal polyp, unspecified). – Prurigo Nodularis: L28.1. Requires documented lesion count and quality of life impact. – COPD: J44.1 (COPD with acute exacerbation). Requires eosinophil count 300+ and documented triple therapy failure.
CPT/HCPCS codes: J3490 (unclassified drugs) is the most common HCPCS code used for Dupixent. 96372 covers the therapeutic subcutaneous injection administration. Office visit E/M codes 99213 or 99214 apply when Dupixent is administered during an office visit. Always confirm the required HCPCS code with Cigna before submission, because code requirements can change with formulary updates. Code mismatches cause preventable administrative denials that waste staff time on corrections.
Cigna vs. Other Payers: How Dupixent PA Differs
Cigna is more likely to apply biologic-preference step therapy for asthma patients, potentially requiring Nucala or Fasenra before Dupixent. UHC and Aetna generally accept ICS/LABA failure without requiring a different biologic first.
The specialty pharmacy routing is where practices feel the most operational difference. Cigna mandates Accredo, UHC uses OptumRx, and Aetna uses CVS Specialty. Each has its own intake process, copay assistance workflow, and patient communication system. Practices prescribing Dupixent across multiple payers must maintain familiarity with all three to avoid access delays.
Common Mistakes That Delay Cigna Dupixent Approvals
Practices that struggle with Cigna Dupixent PAs usually repeat the same five mistakes. Recognizing them in advance prevents weeks of avoidable rework.
Mistake 1: Submitting without referencing IP0453. The single most effective change a practice can make is explicitly citing IP0453 in the letter of medical necessity and mapping each clinical finding to the specific policy criterion it satisfies. Cigna medical reviewers process high volumes. When your submission speaks their policy language back to them, the case is easier to approve.
Mistake 2: Generic step therapy documentation. “Patient failed topical steroids” without drug name, dose, duration, and clinical outcome triggers a near-automatic denial. Every prior therapy needs specificity: the exact drug, the exact dose, the exact dates tried, and the exact reason for discontinuation with objective clinical evidence.
Mistake 3: Ignoring the Accredo handoff. Many practices consider the PA “done” when Cigna issues approval and lose visibility into the Accredo intake process. Patients call the practice frustrated because the medication has not arrived, and the practice has no answer. The PA team should follow up with Accredo within 48 hours of approval to confirm intake is moving and the copay card is applied.
Mistake 4: Letting reauthorization lapse. Cigna requires reauthorization every 12 months. If the reauthorization is submitted late or approved late, the patient’s therapy gets interrupted, and many patients experience disease flare when restarting after a gap. A reliable reauthorization calendar with 60-day and 30-day pre-expiration alerts prevents this.
Mistake 5: Not tracking denial patterns by indication. The denial reasons for atopic dermatitis are different from the denial reasons for asthma or EoE. A practice that tracks denial patterns by indication and adjusts the submission template accordingly sees first-pass approval rates climb over time. Staffingly’s team tracks this pattern data across 800+ providers, which means every Cigna Dupixent submission benefits from the cumulative denial intelligence of the full client base.
How Staffingly Handles Cigna Dupixent PAs for Your Practice
Staffingly PA specialists are trained specifically on Cigna’s IP0453 criteria, CNF 420 PA process, CNF 149 quantity limits, and the Accredo specialty pharmacy workflow. This is not generic PA support. Your assigned team knows the exact documentation Cigna requires by indication, the common denial reasons and how to address each one, and the Accredo intake process that adds days to patient access if not managed proactively.
The full Cigna Dupixent PA lifecycle includes: benefits investigation to confirm plan-level coverage and tier placement, initial PA submission with complete documentation matched to IP0453 criteria, follow-up within 24 to 48 hours of submission to confirm receipt and check status, Accredo coordination after approval to ensure the prescription and copay card are received, denial appeals with structured Letters of Medical Necessity referencing IP0453 by name, peer-to-peer scheduling for the prescribing physician when clinical discussion is needed, and reauthorization tracking with submission 30 days before the 12-month expiration.
800+ providers trust Staffingly for specialty drug PA management. $399/week (volume discounts to $299/week) with 70% cost savings versus in-house PA staff. 99.2% clean claim rate. 48-72 hour go-live from signed agreement. 50+ EHR platforms supported. SOC 2 Type II, HITRUST, ISO 27001, and HIPAA compliant with signed BAA.
What Did We Learn?
Cigna covers Dupixent on the specialty tier with mandatory PA under IP0453. Step therapy varies by indication. Cigna may prefer another biologic first for asthma. Electronic submission produces faster approvals than fax. After approval, Accredo adds 3-7 days. Appeals with peer-to-peer and IP0453 references have high overturn rates (~80% on MA per Cigna CMS data). Texas HB 1763 and Ohio SB 265 give providers step therapy override tools. Staffingly handles the full Cigna PA lifecycle at $399/week (volume discounts to $299/week) with 70% cost savings.
Ready to Cut Prior Authorization and Eligibility Headaches?
Staffingly helps practices like yours get paid faster with a 99.2% clean-claim rate, 65-70% cost savings, and 48-72 hour go-live. SOC 2 Type II, HITRUST, and ISO 27001 certified. HIPAA compliant. MGMA Corporate Member.
- Start a 15-Day Risk-Free Pilot and see results before you commit.
- Call us: (800) 489-5877
